Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia. Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In [...]
Annamaria Staiano Italian Journal of Pediatrics 2017, 43(Suppl 1): A2 Diarrhoea in children still has a major impact on health-related social costs, affecting approximately 2 billion children younger than 5 years every year, and determining 2 million deaths, mostly in Africa and Asia. [1] According to WHO diarrhea consists in [...]
In order to further disseminate its proprietary barrier technology, on which the new concept “mucoprotection” is based, and as part of its continuous investment in its products´ reputation, Noventure has just participated in this year´s ESPGHAN Congress, held in Prague. Pediatric gastroenterologists are a key target group for the recommendation [...]
L. Lopetuso, C. Graziani, A. Guarino, A. Lamborghini, S. Masi, V. Stanghellini Eur Rev Med Pharmacol Sci . 2017; 21 (4): 873-883 Researchers from the A. Gemelli Foundation, School of Medicine, Rome, Italy have published an extensive review on the role of Gelatin tannate and tyndallized probiotics (Tasectan Duo) in [...]
Jess Torres-Herrera, and Gabriel Torres-Ruiz. Current Drug Therapy, 2017, 12, 1-6 Background: Gelatin tannate is bowel selective, safe and effective, and acts locally to form a biofilm. As an adjuvant to oral rehydration solution (ORS), gelatin tannate acts as a mucoprotectant in the management of acute diarrhea in children. Objective: [...]
L. Lopetuso, C. Graziani, A. Guarino, A. Lamborghini, S. Masi, V. Stanghellini Eur Rev Med Pharmacol Sci . 2017; 21 (4): 873-883 Objective: Intestinal permeability impairment is implicated in many gastrointestinal (GI) diseases. Chronic diarrhea, defined as the presence of diarrhea for more than 3 weeks in adults and 2 [...]
Catalin Pleasea Condratovici, Xavier Llop, Núria Piqué, Vladimir Bacarea. 23rd UEG WEEK BARCELONA. October 24-28 2015 [...]
Catalin Pleasea Condratovici, Vladimir C. Bacârea, Núria Piqué. Gastroenterology Research and Practice. April 2016 Background: Xyloglucan, a film-forming agent, improves intestinal mucosa resistance to pathologic damage. The efficacy, safety, and time of onset of the antidiarrheal effect of xyloglucan were assessed in children with acute gastroenteritis receiving oral rehydration solution [...]
Soner Sertan Kara, Burcu Volka2, Ibrahim Erten. G-eP-020. ESPGHAN 50th Annual Meeting – Abstracts. May 2017. Pag 114 Objectives and study: Acute gastroenteritis (AGE) is a common cause of morbidity and mortality worldwide. The management of children and infants with viral AGE mainly depends on oral or intravenous hydration, breastfeeding, [...]
Çağan E, Ceylan S, Mengi Ş, Çağan HH. Med Sci Monit. 2017 Apr 27;23:2029-2034. Background: Acute diarrhea is the second most common cause of morbidity and mortality worldwide, especially in children aged ≤3 years. Some drugs (e.g., the mucoprotector gelatin tannate) plus a reduced osmolality oral rehydration solution (ORS) may [...]